[{"address1": "345 Park Avenue South", "address2": "3rd Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "646 844 0337", "website": "https://www.protaratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.", "fullTimeEmployees": 26, "maxAge": 86400, "priceHint": 4, "previousClose": 2.41, "open": 2.44, "dayLow": 2.26, "dayHigh": 2.58, "regularMarketPreviousClose": 2.41, "regularMarketOpen": 2.44, "regularMarketDayLow": 2.26, "regularMarketDayHigh": 2.58, "beta": 1.899, "forwardPE": -0.5458937, "volume": 383327, "regularMarketVolume": 383327, "averageVolume": 423224, "averageVolume10days": 179720, "averageDailyVolume10Day": 179720, "bid": 2.25, "ask": 2.31, "bidSize": 600, "askSize": 400, "marketCap": 46533400, "fiftyTwoWeekLow": 1.04, "fiftyTwoWeekHigh": 5.24, "fiftyDayAverage": 2.8761, "twoHundredDayAverage": 2.486945, "currency": "USD", "enterpriseValue": -3462654, "floatShares": 13627064, "sharesOutstanding": 20590000, "sharesShort": 1363630, "sharesShortPriorMonth": 398338, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.066199996, "heldPercentInsiders": 0.06181, "heldPercentInstitutions": 0.42153, "shortRatio": 3.32, "shortPercentOfFloat": 0.088199995, "impliedSharesOutstanding": 20590000, "bookValue": 5.108, "priceToBook": 0.44244325, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -42470000, "trailingEps": -3.74, "forwardEps": -4.14, "lastSplitFactor": "1:40", "lastSplitDate": 1578614400, "enterpriseToEbitda": 0.076, "52WeekChange": -0.06611568, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TARA", "underlyingSymbol": "TARA", "shortName": "Protara Therapeutics, Inc.", "longName": "Protara Therapeutics, Inc.", "firstTradeDateEpochUtc": 1413984600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cc0229f5-ebf3-39e0-a4ea-c25aad00f5c1", "messageBoardId": "finmb_545890808", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.26, "targetHighPrice": 50.0, "targetLowPrice": 14.0, "targetMeanPrice": 27.8, "targetMedianPrice": 23.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 55223000, "totalCashPerShare": 2.682, "ebitda": -45385000, "totalDebt": 5227000, "quickRatio": 10.043, "currentRatio": 10.528, "debtToEquity": 8.949, "returnOnAssets": -0.32751998, "returnOnEquity": -0.55452996, "freeCashflow": -18191500, "operatingCashflow": -35048000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]